An observational study in Chronic Kidney Disease and Hypertension, sponsored by King's College London. Recruiting at 1 site in United Kingdom. Open to participants aged 10 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-17.
Sponsored by King's College London · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 229 studies in Renal Insufficiency, Chronic with a site in United Kingdom — 31 open to participants now, 49 under way, 17 of them phase 3. Renal Insufficiency, Chronic · United Kingdom.
Among the 229 studies in Renal Insufficiency, Chronic with a site in United Kingdom, this one is the 27th largest by planned enrollment of the 71 observational ones that give a count, is one of 9 that started in 2026, is one of 71 observational ones, reaches primary completion later than 37 of the 48 other live ones, and was the 227th registered.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
Browse Renal Insufficiency, Chronic studies →31 of the 229 studies in Renal Insufficiency, Chronic with a site in United Kingdom are open now. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 18+
AstraZeneca · Sites in United Kingdom, United States, Argentina and 24 more countries
Ages 18–99
AstraZeneca · Sites in United Kingdom, United States, Argentina and 34 more countries
Ages 18+
Vifor Fresenius Medical Care Renal Pharma · Sites in United Kingdom, China, Greece and 4 more countries
Ages 12–18
Portsmouth Hospitals NHS Trust · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.
This study: 10 Years to 25 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
229 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 39 · Phase 3 69 · Phase 4 11
First in 2003; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is close to the median of 213 across 835 observational studies indexed under Renal Insufficiency, Chronic.
Median enrollment 139 across the 158 interventional studies, 119 across the 71 observational. Of the 155 that completed or were terminated, 72 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
120 of 229 have an industry lead sponsor. The 10 most frequent:
King's College London is the lead sponsor of 522 studies on the registry; 128 are open to participants now.
King's College London has 5 studies filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
17 of the studies in Renal Insufficiency, Chronic with a site in United Kingdom that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06531824Phase 3Boehringer IngelheimEASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | 2026-12-31 |
| NCT05196035Phase 3BayerA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | 2027-04-10 |
| NCT07107945Phase 3Boehringer IngelheimA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | 2027-04-16 |
| NCT03969329Phase 3AmgenA Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis | 2027-06-30 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
Add all 17 to your calendar (.ics) → With an account.
Among the 229 studies in Renal Insufficiency, Chronic with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Age related stiffening and hardening of the arteries is often a slow process, but some conditions such as chronic kidney disease (CKD), seem to increase the rate at which the arteries stiffen even during childhood. High blood pressure (BP) is well known to lead to arterial stiffening and is often seen in children and young people (CYP) with CKD.
A greater risk of arterial stiffening has been reported in children CYP with CKD compared to healthy CYP and this is thought to be related to the development of high BP, heart problems, and the worsening of kidney damage. The cause is unknown and is unlikely due to age related changes in the arterial wall seen in older adults. Potential mechanisms contributing to arterial stiffening in CYP with CKD include i) abnormalities in the interaction between the heart and the aorta (the large artery pumping blood away from the heart to the rest of the body), overactivity of the sympathetic nervous system (SNS), the body's "stress response", or iii) abnormal metabolism seen in CKD, where there are high levels of phosphate and other waste products circulating in the blood as a result of damage to the kidneys.
In this study, the investigators will use a variety of non invasive experimental methods to determine if arterial stiffening seen in CYP with CKD is due solely to increased BP, or whether the other potential factors listed above also contribute. This may help to eventually identify how to prevent or treat arterial stiffness in CYP with CKD and prevent its adverse impact on kidney and heart health in later life. The investigators will compare findings between those with CKD and an age, sex and BP matched control group. This control group will comprise CYP both with high BP (primary hypertension) and without high BP (healthy participants).
Methods:
Single time point assessment of aortic stiffness of children and young people with CKD; recruitment target of in total 100 participants, of which: 50 pre-dialysis (CKD stage 1-5), 25 on dialysis (CKD stage 5D) and 25 with kidney transplant (CKD-T) compared to 100 age-, sex- and BP-matched controls. Controls will be sourced from existing funded studies performing similar measurements on young people with primary hypertension and healthy normotensive controls, allowing the investigators to match CKD participants to a control group from across the blood pressure (BP) spectrum.
Longitudinal follow-up for one additional timepoint will be offered to all CKD participants with BP >75th percentile (or >130/80 mmHg in adults). The investigators expect this to be around 25 children and young people over the study time period.
All participants will undergo the following investigations:
Assessments will then be repeated in the CKD study group once BP \<75th percentile (or \<130/80 mmHg in adults) is achieved.
In a subset of study participants (n = 25 for each additional intervention), some additional investigations will be performed optionally at the discretion of researchers, patients and families:
Study visits:
Potential participants will be identified from established CKD clinics and recruited with the help of a study coordinator based at Evelina London Children's Hospital (ELCH). Young adults with CKD will be recruited with the help of the well-established transition and adult CKD clinic at Guy's Hospital, with whom there are long- standing collaborations. Routinely, most children with moderate CKD will be seen at least once every 3-6 months.
Control participants will be included from a contemporaneously funded parallel study and include both children with primary hypertension and healthy normotensive children who have consented for their anonymised research data to be used in other ethically approved studies.
The investigators anticipate study consent and some routine clinic testing to be performed at the time of a planned clinic visit but detailed research related investigations including MRI may require an additional planned study visit lasting 2-4 hours at baseline and again at follow up for each complete set of research investigations. Visits will be conducted at dedicated child and adult Clinical Research Facilities as appropriate.
Participants will visit their usual hospital, have no extra needle pricks for blood tests, have non-invasive research tests offered at flexible timings and be compensated for their time and travel.
As this is an observational study, no study related change in the management of participants will be made.
Following achievement of clinical BP target (\<75th percentile or \<130/80mmHg in adults), assessments similar to baseline will be repeated in all participants and experimental interventions in a subset.
Sample size determination and statistical analysis:
Primary outcome: The mean difference in cfPWV between CYP with pre-dialysis CKD and age/sex/BP matched controls is expected to be \~ 0.8 m/s and with n = 50 in each group and a between-subject SD of 0.7 m/s (in-house from our HOT KID controls), the study will have 80% power (for p \< 0.05) of detecting a difference > 0.4 m/s.
Interventional studies: a sample size n = 25 has similar power to detect a change >0.6 of the within-subject SD for differences in cfPWV, which for a within-subject SD of 0.5 m/s is 0.3 m/s, approximately 50% of the difference between hypertensive and normotensive CYP with CKD.
Longitudinal follow-up: within-subject SD is expected to be slightly greater, but this is offset by the greater sample size, and the investigators expect power to be similar to detect a change of 0.3 m/s, 50% of the difference between CYP with CKD and age-, sex- and BP-matched controls.
Recruitment of dialysis and transplant patients is exploratory at this stage and will generate pilot data, therefore for this study they were not included in the power calculation.
The primary outcome measure will be assessed by students t test and ANOVA, with and without adjustment for confounders including age, sex, ethnicity, renal function, heart rate, use of antihypertensive and BMI.
Effects of interventions and change in outcomes after follow-up will be assessed by repeated measures ANOVA.
Significance is defined as P \< 0.05.
Children and young adults with chronic kidney disease and age-, sex- and gender-matched healthy controls and those with primary hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For CKD participants:
For controls:
Exclusion criteria (for all participants):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Children and young adults with chronic kidney disease: * 50 pre-dialysis (CKD stage 1-5) * 25 on dialysis (CKD stage 5D) * 25 with kidney transplant (CKD-T).
sex and BP matched control participants comprising both young people with primary hypertension and healthy normotensive
Difference in carotid femoral pulse wave velocity
The difference in carotid femoral pulse wave velocity (m/s) between children and young adults with CKD and age, sex and blood pressure (BP) matched controls.
Time frame: Baseline (single time point)
Difference in carotid femoral pulse wave velocity once blood pressure is normalised
The difference in carotid femoral pulse wave velocity (m/s) pre and post anti-hypertensive therapy in children and young adults with CKD.
Time frame: Baseline; Post anti-hypertensive therapy when a clinical blood pressure target of <75th percentile or <130/80mmHg in adults is achieved (anticipated to be 6-9 months post baseline).
Difference in sympathetic nerve activity
The difference in markers of sympathetic nerve activity between children and young people with CKD compared to age, sex and BP matched controls as follows: * Plasma catecholamines. * Pulse wave velocity (m/s) difference pre and post device guided slow breathing (DGB). * Pulse wave velocity (m/s) difference pre and post lower limb venous occlusion (LVO)
Time frame: Baseline (single time point)
Difference in aortic pulse wave velocity
The difference in aortic pulse wave velocity (m/s) as measured by MRI between children and young adults with CKD and age, sex and BP matched controls.
Time frame: Baseline (single time point)
Difference in cardiac output - echocardiography
The difference in cardiac output between CYP with CKD and age, sex and BP matched controls as measured by: Echocardiography
Time frame: Baseline (single time point)
Difference in cardiac output - Cardiac MRI
The difference in cardiac output between CYP with CKD and age, sex and BP matched controls as measured by: Cardiac MRI
Time frame: Baseline (single time point)
Plan to share: No — IPD will not be shared beyond the study team.
Started Jun 2026 (actual). Primary completion is estimated for Jun 2028, 24 months after the start.
Of 274 non-industry observational studies under Renal Insufficiency, Chronic, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 192. This study's planned 24 months is below that.
Counting every sponsor, half of 325 studies reached it within 45 months; a quarter within 22 and three quarters within 191.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →